A new generation of therapies aims to intervene at a recently discovered gap between the disease’s molecular march and its ...

QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its ...

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.

Prilenia Therapeutics and Ferrer have begun the confirmatory Phase III PRECISE-HD clinical trial assessing pridopidine as a ...

Medically reviewed by Nicholas R. Metrus, MD Key Takeaways Huntington’s disease is a genetic disorder that you can inherit ...

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline ...

Huntington’s disease (HD) is one of those rare conditions that affects not just the patient but the entire family—medically, emotionally and genetically. This inherited brain disorder causes gradual ...

These two programme terminations leave Roche with just one Huntington’s disease candidate.

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately 20 years before a clinical motor diagnosis in people with Huntington's disease, ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. People affected by Huntington’s disease could at last benefit from the ...